Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06556173 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of VTX3232 in Parkinson's Disease
A Phase 2 study, sponsored by Zomagen Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT06556173 is a Phase 2 study that has completed, run by Zomagen Biosciences. The registered enrollment target is 11 participants.
The verdict
NCT06556173, a Phase 2 study, has completed, sponsored by Zomagen Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-Baseline Period, a 28-day Open Label Treatment period (a participant receives active Dose A), and a 14-day Follow-Up Period.
Interventions
- DRUG VTX3232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2025-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06556173
The ClinicalTrials.gov registry entry for NCT06556173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zomagen Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VTX3232 is the first listed.
NCT06556173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06556173 about?
NCT06556173 is a clinical study titled "Phase 2a Study of VTX3232 in Parkinson's Disease". This is a study to understand if taking VTX3232 is safe in participants diagnosed with early stage idiopathic Parkinson's Disease (PD). Approximately 10 patients will take VTX3232 Dose A. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 7-day Pre-...
What is the current status of trial NCT06556173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2024-08-08. Estimated completion is 2025-04-04.
What interventions are being tested in trial NCT06556173?
The interventions under investigation include: VTX3232 (DRUG).
Who is sponsoring clinical trial NCT06556173?
This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.